<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892229</url>
  </required_header>
  <id_info>
    <org_study_id>IMS - 1769</org_study_id>
    <nct_id>NCT00892229</nct_id>
  </id_info>
  <brief_title>Buccal Versus Vaginal Misoprostol in Surgical Termination of the First Trimester Missed Abortion in Erbil</brief_title>
  <official_title>Buccal Versus Vaginal Misoprostol for Cervical Ripening Prior to Surgical Termination of the First Trimester Missed Abortion in Erbil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hawler Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NEGATIVE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hawler Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of buccal misoprostol and
      comparing this with vaginal route of the same drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficacy of buccal administration to the more commonly vaginal route for preoperative cervical and priming in patients with first trimester surgical abortion. (Buccal Vs. Vaginal Misoprostol in the First Trimester Missed Abortion.)</measure>
    <time_frame>March 2007 to March 2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives are to compare the side effects and acceptability by the subjects.</measure>
    <time_frame>March 2007 to March 2008</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Missed Abortion</condition>
  <arm_group>
    <arm_group_label>Buccal Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group one: 50 patients with first trimester missed abortion received buccal misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group two: 5 patients received vaginal misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buccal and Vaginal Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 primiparous and 50 multiparous women: one hundred patients have been administered the medication buccally (25 primigravida and 25 multigravida), and vaginally (25 primigravida and 25 multigravida), three hours before dilation and curettage. They were admitted to the hospital one day before the surgical evacuation, and preparation of cross matched blood done for all recruited subjects.
Each group was randomly allocated (1,3,5,... for the buccal group &amp; 2,4,6,... for the vaginal group) to receive 400 microgram misoprostol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol (given buccally)</intervention_name>
    <description>400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)</description>
    <arm_group_label>Buccal Misoprostol</arm_group_label>
    <arm_group_label>Buccal and Vaginal Misoprostol</arm_group_label>
    <other_name>serial number 022-00</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol (given vaginally)</intervention_name>
    <description>400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)</description>
    <arm_group_label>Vaginal Misoprostol</arm_group_label>
    <arm_group_label>Buccal and Vaginal Misoprostol</arm_group_label>
    <other_name>serial number 022-00</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first trimester missed abortion

        Exclusion Criteria:

          -  history or evidence of disorders that represent contraindication to the use of
             misoprostol:

               -  severe pulmonary diseases

               -  congenital or acquired heart diseases

               -  glaucoma

               -  prolonged use of corticosteroid

               -  sickle cell anemia and adrenal insufficiency

               -  smokers

               -  known hypersensitivity to drugs

               -  any evidence of infection

          -  patient's refusal to participate in the study

          -  patients with abnormal results of investigations

          -  patients with previous operations on cervix like conisation, cauterization, previous
             dilatation and curettage

          -  patients with complete abortion

          -  patients with severe bleeding that required emergency surgical evacuation of the
             uterus

          -  patients with partially dissolved tablets at the site of application in both groups
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BASHAR Y F HANOOSHI, CABOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRAQI MEDICAL SPECIALIZATION/IRAQ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Iraqi Medical Specialization</name>
      <address>
        <city>Risafa</city>
        <state>Baghdad</state>
        <zip>00964</zip>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2009</study_first_submitted>
  <study_first_submitted_qc>May 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2009</study_first_posted>
  <last_update_submitted>May 1, 2009</last_update_submitted>
  <last_update_submitted_qc>May 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. NADA S AMEEN - THE CHAIRWOMEN</name_title>
    <organization>IRAQI MEDICAL SPECIALIZATION</organization>
  </responsible_party>
  <keyword>First trimester missed abortion</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>buccal</keyword>
  <keyword>vaginal</keyword>
  <keyword>cervical ripening</keyword>
  <keyword>first trimester</keyword>
  <keyword>missed abortion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Missed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

